remdesivir
Gilead’s Veklury recommended by NICE for COVID-19 treatment
April 9, 2024Medical Communications COVID-19, Gilead Sciences, Infections and infestations, remdesivir
Gilead Sciences has announced that the National Institute of Health and Care Excellence (NICE) has recommended the use of Veklury …
Jubilant’s oral remdesivir formulation shows positive results in human trial
April 22, 2021COVID-19, Gilead, Jubilant Pharma, covid-19 treatment, pharma, pharma news, remdesivir
Jubilant Pharma has announced the successful completion of studies in human volunteers for their oral formulation of remdesivir – an …
Pharmafile.com’s weekly COVID-19 news round-up
November 4, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, GSK, Sanofi, UK, US, remdesivir
As European nations fall one by one back into lockdown, hopes weigh heavily on a vaccine to pave a path …
The November 2020 issue of Pharmafocus is available to read free online now!
October 27, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, Biden, Pharmafocus, Trump, UK, US election, brexit, pharma, remdesivir
The latest monthly edition of Pharmafocus is available to read for free online now!
FDA approves Gilead’s remdesivir for hospitalised COVID-19 patients
October 23, 2020Medical Communications, Sales and Marketing COVID-19, FDA, Gilead, remdesivir
The FDA has approved Gilead’s antiviral therapy Veklury (remdesivir) for the treatment of hospitalised COVID-19 patients, making it the first …
European Commission stands by €1bn remdesivir supply deal despite disappointing COVID-19 benefit
October 19, 2020Manufacturing and Production, Sales and Marketing COVID-19, Europe, Gilead, remdesivir
As Europe continues to face down a rising second wave of COVID-19, the European Commission quickly moved to secure a …
Gilead’s remdesivir and three other repurposed drugs have no impact on COVID-19 mortality, WHO study finds
October 16, 2020Medical Communications, Research and Development COVID-19, pharma, remdesivir
Gilead’s antiviral therapy remdesivir has emerged as one of the most promising drugs to treat COVID-19 infections, but recent studies …
Remdesivir has a “favourable” benefit/risk profile in COVID-19 but more data needed, DSRU review argues
October 5, 2020Research and Development, Sales and Marketing COVID-19, Drug Safety Research Unit, pharma, remdesivir
Southampton’s Drug Safety Research Unit (DSRU) has released a systematic benefit/risk analysis of Gilead’s antiviral drug remdesivir in the treatment …
Lilly’s baricitinib/remdesivir combo lowers recovery time in hospitalised COVID-19 patients, according to new data
September 15, 2020Manufacturing and Production, Research and Development COVID-19, Eli Lilly, pharma, remdesivir
Eli Lilly has unveiled promising new data from a study investigating the efficacy of baricitinib when combined with with Gilead’s …
Racial minority groups are not adequately represented in COVID-19 clinical studies, research argues
August 12, 2020Research and Development COVID-19, Gilead, pharma, remdesivir
New research has warned that minority groups and people of colour are underrepresented in current trials for COVID-19 therapies, despite …
Mylan launches generic version of Gilead’s remdesivir for COVID-19 patients in India
July 20, 2020Sales and Marketing COVID-19, Gilead, India, Mylan, generic, remdesivir
Mylan has launched its own generic version of Gilead’s remdesivir on the Indian market for the treatment of patients with …
New data shows Gilead’s remdesivir “potently inhibited” SARS-CoV-2 in human lung cell cultures
July 10, 2020Medical Communications, Research and Development COVID-19, Gilead, coronavirus, remdesivir
New findings published from researchers at Vanderbilt University Medical Center (VUMC) at the University of North Carolina, as well as …
Gilead’s remdesivir becomes first EU-recommended therapy for COVID-19
June 26, 2020Medical Communications, Sales and Marketing COVID-19, EU Gilead, remdesivir
In a crucial step amidst the ongoing pandemic, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) …
Gilead to investigate inhaled formulation of promising COVID-19 therapy remdesivir
June 23, 2020Manufacturing and Production, Research and Development COVID-19, Gilead, remdesivir
Gilead is intent on pushing the applications of its antiviral drug remdesivir after it has shown efficacy in the treatment …
EMA could approve Gilead’s streamlined remdesivir application for COVID-19 “within weeks”
June 9, 2020Manufacturing and Production, Sales and Marketing COVID-19, EU, Gilead, coronavirus, remdesivir
The European Medicines Agency has received the application from Gilead for the first conditional marketing authorisation (CMA) of its antiviral …
